Byk-Mallinckrodt CIL
As of the edition of 20 October 2026, Byk-Mallinckrodt CIL runs 47 drugs, 39 of them marketed; it is on route A at 0 targets and on route B at 6 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
Byk-Mallinckrodt CIL was renamed in 2011.
The records place 4 company names in this family.
- Byk-Mallinckrodt CIL B.V.: renamed in 2011
- Cadence Pharmaceuticals: acquired in 2014; successor Byk-Mallinckrodt CIL B.V.
- Sucampo Pharmaceuticals, Inc.: acquired in 2018; successor Byk-Mallinckrodt CIL B.V.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 39 |
| Went quiet | 3 |
| Stopped | 4 |
| Status not established | 1 |
| Total | 47 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Acetaminophen | none listed | 17 |
| Morphine | none listed | 2 |
| Sodium chloride | none listed | 0 |
| Methylphenidate | none listed | 11 |
| Methadone | none listed | 2 |
| Albumin human | none listed | 0 |
| Nitric oxide | Ends 2029 (patent) | 4 |
| Hydromorphone | none listed | 1 |
| Corticotropin | none listed | 1 |
| Terlipressin | Ends 2029 (exclusivity) | 3 |
| Xenon | none listed | 0 |
| Lubiprostone | none listed | 1 |
| Sodium phosphate, dibasic, anhydrous | none listed | 0 |
| Selenomethionine | none listed | 0 |
| Technetium tc 99m sulfur colloid | none listed | 0 |
| Sodium iodide | none listed | 0 |
| Ioversol | none listed | 0 |
| Gallium citrate | none listed | 0 |
| Indium pentetreotide | none listed | 5 |
| Gadoversetamide | none listed | 0 |
| Iodohippurate | none listed | 0 |
| Sodium sulfide | none listed | 0 |
| Unoprostone isopropyl | none listed | 0 |
| Sodium chromate | none listed | 0 |
| Sodium pertechnetate | none listed | 0 |
A route B row is one company at one target. 14 more marketed drugs are not listed here.
Where it needs a new molecule
Route A at 0 targets, route B at 6 targets.
All 6 rows on route A or B
In the product6 company-target rows on route A or B; 3 are not shown here, and no score is.
See all 6 targets where Byk-Mallinckrodt CIL needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Digestive system: 9 trials led
- Bones, joints and muscles: 5 trials led
- Chemically induced: 5 trials led